528 related articles for article (PubMed ID: 27729738)
1. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients.
Lee HW; Ahn SH
World J Gastroenterol; 2016 Oct; 22(37):8314-8321. PubMed ID: 27729738
[TBL] [Abstract][Full Text] [Related]
2. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
3. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
[TBL] [Abstract][Full Text] [Related]
4. APS (Age, Platelets, 2D Shear-Wave Elastography) Score Predicts Hepatocellular Carcinoma in Chronic Hepatitis B.
Zhang T; Zhang G; Deng X; Zeng J; Jin J; Zeping H; Wu M; Zheng R
Radiology; 2021 Nov; 301(2):350-359. PubMed ID: 34427463
[TBL] [Abstract][Full Text] [Related]
5. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.
Yang HI; Tseng TC; Liu J; Lee MH; Liu CJ; Su TH; Batrla-Utermann R; Chan HL; Kao JH; Chen CJ
Clin Gastroenterol Hepatol; 2016 Mar; 14(3):461-468.e2. PubMed ID: 26598229
[TBL] [Abstract][Full Text] [Related]
6. Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues.
Tawada A; Chiba T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Arai M; Kanda T; Shinozaki M; Goto N; Nagashima K; Yokosuka O
Oncology; 2016; 90(4):199-208. PubMed ID: 26934505
[TBL] [Abstract][Full Text] [Related]
7. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
[TBL] [Abstract][Full Text] [Related]
8. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?
Wong VW; Janssen HL
J Hepatol; 2015 Sep; 63(3):722-32. PubMed ID: 26026875
[TBL] [Abstract][Full Text] [Related]
9. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.
Yuen MF; Tanaka Y; Fong DY; Fung J; Wong DK; Yuen JC; But DY; Chan AO; Wong BC; Mizokami M; Lai CL
J Hepatol; 2009 Jan; 50(1):80-8. PubMed ID: 18977053
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B.
Jeon MY; Lee HW; Kim SU; Kim BK; Park JY; Kim DY; Han KH; Ahn SH
Liver Int; 2018 Apr; 38(4):676-686. PubMed ID: 28865176
[TBL] [Abstract][Full Text] [Related]
11. What can we learn from hepatitis B virus clinical cohorts?
Lin CL; Tseng TC; Kao JH
Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
[TBL] [Abstract][Full Text] [Related]
12. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yang HI; Sherman M; Su J; Chen PJ; Liaw YF; Iloeje UH; Chen CJ
J Clin Oncol; 2010 May; 28(14):2437-44. PubMed ID: 20368541
[TBL] [Abstract][Full Text] [Related]
13. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
[TBL] [Abstract][Full Text] [Related]
14. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy.
Jung KS; Kim SU; Song K; Park JY; Kim DY; Ahn SH; Kim BK; Han KH
Hepatology; 2015 Dec; 62(6):1757-66. PubMed ID: 26249025
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
[TBL] [Abstract][Full Text] [Related]
16. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B: liver fibrosis and hepatocellular carcinoma.
Lok AS
Gastroenterol Clin Biol; 2009; 33(10-11):911-5. PubMed ID: 19577871
[TBL] [Abstract][Full Text] [Related]
18. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
Chen TM; Chang CC; Huang PT; Wen CF; Lin CC
Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
[TBL] [Abstract][Full Text] [Related]
19. Natural history of chronic hepatitis B: what exactly has REVEAL revealed?
Iloeje UH; Yang HI; Chen CJ
Liver Int; 2012 Oct; 32(9):1333-41. PubMed ID: 22510145
[TBL] [Abstract][Full Text] [Related]
20. The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
Hu HH; Liu J; Lin YL; Luo WS; Chu YJ; Chang CL; Jen CL; Lee MH; Lu SN; Wang LY; You SL; Yang HI; Chen CJ;
Gut; 2016 Sep; 65(9):1514-21. PubMed ID: 26642861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
